PRESENTATION OF THE COMPANY

ANI intellectual property (IP) is based on a portfolio of Active Nutrigenomic Ingredients (“ANI”) that has been protected through international patent applications. The most developed  ANIs address important public health issues, respectively the metabolic syndrome pandemic, immune system weakening, imbalance of bone metabolism (osteopenia, osteoporosis), and sleep disorders. Their beneficial effects have already been proven in preclinical studies, open human clinical trials, and for some of them double blind studies.

They are all natural ingredients, which, taken separately, are EFSA- and FDA-compliant, and have been approved for human consumption in much larger quantities than the ones used in ANIs. Thus, although ANI is a biotechnology company, it does not have the high-risk profile associated with biotech companies developing pharmaceutical drugs, which concern drug efficacy in human and toxic side effects.

The portfolio of Active Nutrigenomic Ingredients represents a very important development in several markets, in particular in the functional food market, where they can rapidly gain market shares, sometimes in conjunction with existing ingredients. In the healthcare market, ANIs can be introduced in the diet as nutraceutical supplements or functional foods, alone, or used in combination with blockbuster drugs. In the field of mass nutrition, they are designed to provide cost-effective solutions to nutritional and health issues in developing countries. Several African nations have indeed already expressed interest in ANI’ immune system-strengthening.